At the 2024 China Biotech Innovation Conference, the 2024 China Biopharmaceutical Industry Park Competitiveness Evaluation and Analysis Report was officially released. This report, ranking the nation’s top 50 biopharmaceutical industry parks for 2023, placed Changzhou West Taihu Lake Science and Technology Industrial Zone at 30th position, making it the only provincial-level economic development zone to feature on the list.
The report underscores the importance of biopharmaceutical industry parks as critical platforms for advancing China's high-quality development. Conducted by the China National Center for Biotechnology Development, alongside specialized institutions and think tanks, the evaluation assessed 206 parks, including 112 national-level high-tech zones, 77 national-level economic development zones, and 16 provincial-level parks. The rankings were derived from a comprehensive analysis of 237 data points spanning 39 themes, such as industrial development, R&D investment, talent, and environmental factors.
Key findings highlight regional clustering trends in the biopharmaceutical industry, with the Yangtze River Delta, Pearl River Delta, and Bohai Rim emerging as major hubs. National high-tech zones led the way, contributing 87% of the sector's output, with the top 20 parks showcasing exceptional talent and resource concentration.
The Changzhou West Taihu Lake Science and Technology Industrial Zone has strategically positioned itself as a leader in medical devices, biopharmaceuticals, cell and gene therapies, and synthetic biology. Anchored by the National Medical Device International Innovation Park, the zone supports over 400 companies and boasts nearly 600 medical device product registrations at or above Class II. Its dynamic ecosystem not only enhances Changzhou’s industrial competitiveness but also contributes significantly to the local economy’s growth and stability.
扫一扫在手机打开当前页  |
